|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HCK |
Gene summary for HCK |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HCK | Gene ID | 3055 |
| Gene name | HCK proto-oncogene, Src family tyrosine kinase | |
| Gene Alias | JTK9 | |
| Cytomap | 20q11.21 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P08631 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3055 | HCK | LZE4T | Human | Esophagus | ESCC | 1.79e-06 | 2.48e-01 | 0.0811 |
| 3055 | HCK | LZE7T | Human | Esophagus | ESCC | 1.90e-07 | 4.59e-01 | 0.0667 |
| 3055 | HCK | P4T-E | Human | Esophagus | ESCC | 1.07e-04 | 1.77e-01 | 0.1323 |
| 3055 | HCK | P5T-E | Human | Esophagus | ESCC | 2.76e-04 | 7.16e-02 | 0.1327 |
| 3055 | HCK | P8T-E | Human | Esophagus | ESCC | 6.93e-06 | 3.37e-01 | 0.0889 |
| 3055 | HCK | P10T-E | Human | Esophagus | ESCC | 3.14e-02 | 2.80e-02 | 0.116 |
| 3055 | HCK | P15T-E | Human | Esophagus | ESCC | 3.61e-03 | 1.60e-01 | 0.1149 |
| 3055 | HCK | P21T-E | Human | Esophagus | ESCC | 1.11e-24 | 5.81e-01 | 0.1617 |
| 3055 | HCK | P22T-E | Human | Esophagus | ESCC | 1.21e-06 | 1.13e-01 | 0.1236 |
| 3055 | HCK | P23T-E | Human | Esophagus | ESCC | 6.22e-04 | 2.45e-01 | 0.108 |
| 3055 | HCK | P26T-E | Human | Esophagus | ESCC | 3.50e-40 | 9.22e-01 | 0.1276 |
| 3055 | HCK | P27T-E | Human | Esophagus | ESCC | 6.69e-04 | 1.48e-01 | 0.1055 |
| 3055 | HCK | P28T-E | Human | Esophagus | ESCC | 6.34e-20 | 4.39e-01 | 0.1149 |
| 3055 | HCK | P30T-E | Human | Esophagus | ESCC | 7.79e-21 | 6.86e-01 | 0.137 |
| 3055 | HCK | P32T-E | Human | Esophagus | ESCC | 1.47e-02 | 1.18e-01 | 0.1666 |
| 3055 | HCK | P42T-E | Human | Esophagus | ESCC | 3.11e-02 | 1.12e-01 | 0.1175 |
| 3055 | HCK | P47T-E | Human | Esophagus | ESCC | 7.13e-09 | 8.26e-02 | 0.1067 |
| 3055 | HCK | P48T-E | Human | Esophagus | ESCC | 3.22e-08 | 1.65e-01 | 0.0959 |
| 3055 | HCK | P49T-E | Human | Esophagus | ESCC | 4.73e-04 | 6.17e-01 | 0.1768 |
| 3055 | HCK | P52T-E | Human | Esophagus | ESCC | 1.50e-07 | 3.44e-01 | 0.1555 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0043254111 | Esophagus | ESCC | regulation of protein-containing complex assembly | 278/8552 | 428/18723 | 3.81e-16 | 2.77e-14 | 278 |
| GO:0031334111 | Esophagus | ESCC | positive regulation of protein-containing complex assembly | 166/8552 | 237/18723 | 2.06e-14 | 1.07e-12 | 166 |
| GO:1902905111 | Esophagus | ESCC | positive regulation of supramolecular fiber organization | 142/8552 | 209/18723 | 5.51e-11 | 1.76e-09 | 142 |
| GO:1902903111 | Esophagus | ESCC | regulation of supramolecular fiber organization | 237/8552 | 383/18723 | 9.06e-11 | 2.75e-09 | 237 |
| GO:005149520 | Esophagus | ESCC | positive regulation of cytoskeleton organization | 147/8552 | 226/18723 | 2.93e-09 | 6.38e-08 | 147 |
| GO:0051258111 | Esophagus | ESCC | protein polymerization | 183/8552 | 297/18723 | 1.94e-08 | 3.75e-07 | 183 |
| GO:000701527 | Esophagus | ESCC | actin filament organization | 259/8552 | 442/18723 | 2.37e-08 | 4.50e-07 | 259 |
| GO:0032273111 | Esophagus | ESCC | positive regulation of protein polymerization | 95/8552 | 138/18723 | 2.97e-08 | 5.57e-07 | 95 |
| GO:003253520 | Esophagus | ESCC | regulation of cellular component size | 227/8552 | 383/18723 | 4.77e-08 | 8.60e-07 | 227 |
| GO:0032970111 | Esophagus | ESCC | regulation of actin filament-based process | 231/8552 | 397/18723 | 2.91e-07 | 4.20e-06 | 231 |
| GO:0032956111 | Esophagus | ESCC | regulation of actin cytoskeleton organization | 210/8552 | 358/18723 | 4.40e-07 | 6.00e-06 | 210 |
| GO:00510908 | Esophagus | ESCC | regulation of DNA-binding transcription factor activity | 252/8552 | 440/18723 | 5.22e-07 | 6.97e-06 | 252 |
| GO:0032271111 | Esophagus | ESCC | regulation of protein polymerization | 143/8552 | 233/18723 | 9.21e-07 | 1.17e-05 | 143 |
| GO:011005327 | Esophagus | ESCC | regulation of actin filament organization | 166/8552 | 278/18723 | 1.54e-06 | 1.85e-05 | 166 |
| GO:00028318 | Esophagus | ESCC | regulation of response to biotic stimulus | 191/8552 | 327/18723 | 2.12e-06 | 2.45e-05 | 191 |
| GO:004677710 | Esophagus | ESCC | protein autophosphorylation | 138/8552 | 227/18723 | 2.98e-06 | 3.38e-05 | 138 |
| GO:190211514 | Esophagus | ESCC | regulation of organelle assembly | 116/8552 | 186/18723 | 3.15e-06 | 3.53e-05 | 116 |
| GO:003153218 | Esophagus | ESCC | actin cytoskeleton reorganization | 72/8552 | 107/18723 | 5.03e-06 | 5.31e-05 | 72 |
| GO:002260420 | Esophagus | ESCC | regulation of cell morphogenesis | 180/8552 | 309/18723 | 5.19e-06 | 5.45e-05 | 180 |
| GO:003083819 | Esophagus | ESCC | positive regulation of actin filament polymerization | 66/8552 | 99/18723 | 1.96e-05 | 1.72e-04 | 66 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05167211 | Esophagus | ESCC | Kaposi sarcoma-associated herpesvirus infection | 136/4205 | 194/8465 | 4.28e-09 | 4.22e-08 | 2.16e-08 | 136 |
| hsa0466620 | Esophagus | ESCC | Fc gamma R-mediated phagocytosis | 63/4205 | 97/8465 | 1.63e-03 | 4.89e-03 | 2.50e-03 | 63 |
| hsa0516738 | Esophagus | ESCC | Kaposi sarcoma-associated herpesvirus infection | 136/4205 | 194/8465 | 4.28e-09 | 4.22e-08 | 2.16e-08 | 136 |
| hsa04666110 | Esophagus | ESCC | Fc gamma R-mediated phagocytosis | 63/4205 | 97/8465 | 1.63e-03 | 4.89e-03 | 2.50e-03 | 63 |
| hsa0466618 | Oral cavity | OSCC | Fc gamma R-mediated phagocytosis | 60/3704 | 97/8465 | 2.35e-04 | 7.72e-04 | 3.93e-04 | 60 |
| hsa0466619 | Oral cavity | OSCC | Fc gamma R-mediated phagocytosis | 60/3704 | 97/8465 | 2.35e-04 | 7.72e-04 | 3.93e-04 | 60 |
| hsa05167210 | Oral cavity | LP | Kaposi sarcoma-associated herpesvirus infection | 84/2418 | 194/8465 | 6.66e-06 | 5.16e-05 | 3.33e-05 | 84 |
| hsa0516737 | Oral cavity | LP | Kaposi sarcoma-associated herpesvirus infection | 84/2418 | 194/8465 | 6.66e-06 | 5.16e-05 | 3.33e-05 | 84 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HCK | SNV | Missense_Mutation | novel | c.651N>A | p.Ser217Arg | p.S217R | protein_coding | tolerated(0.4) | benign(0.419) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR | |
| HCK | SNV | Missense_Mutation | rs760472522 | c.1475N>A | p.Arg492His | p.R492H | protein_coding | tolerated(0.11) | probably_damaging(0.998) | TCGA-A8-A0A1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| HCK | insertion | Frame_Shift_Ins | novel | c.1485_1486insGTGATGG | p.Asn496ValfsTer20 | p.N496Vfs*20 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| HCK | SNV | Missense_Mutation | rs774033506 | c.1240C>T | p.Arg414Trp | p.R414W | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-EA-A3Y4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| HCK | SNV | Missense_Mutation | c.121N>A | p.Glu41Lys | p.E41K | protein_coding | tolerated(0.25) | benign(0.025) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | ||
| HCK | SNV | Missense_Mutation | novel | c.463N>C | p.Glu155Gln | p.E155Q | protein_coding | deleterious(0.03) | possibly_damaging(0.761) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| HCK | SNV | Missense_Mutation | novel | c.517N>T | p.Ser173Cys | p.S173C | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| HCK | SNV | Missense_Mutation | c.1303N>G | p.Thr435Ala | p.T435A | protein_coding | deleterious(0) | benign(0.199) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
| HCK | SNV | Missense_Mutation | c.893N>T | p.Ser298Leu | p.S298L | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
| HCK | SNV | Missense_Mutation | novel | c.1291N>G | p.Phe431Val | p.F431V | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3055 | HCK | TYROSINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | LIF | 8156996 | ||
| 3055 | HCK | TYROSINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL3545085 | XL-228 | |
| 3055 | HCK | TYROSINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | AG-1879 | CHEMBL406845 | ||
| 3055 | HCK | TYROSINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL1421 | DASATINIB | |
| 3055 | HCK | TYROSINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | 249565693 | ||
| 3055 | HCK | TYROSINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | MASITINIB | MASITINIB | ||
| 3055 | HCK | TYROSINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL288441 | BOSUTINIB | |
| 3055 | HCK | TYROSINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL52885 | ENMD-981693 | |
| 3055 | HCK | TYROSINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | SB19065 | |||
| 3055 | HCK | TYROSINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | 3-(6-allyloxy-2-naphthyl)-1-(4-piperidylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine |
| Page: 1 2 3 4 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |